Posted by Michael Wonder on 27 Oct 2022
ITM receives FDA fast track designation for radionuclide therapy candidate ITM-11 (Lutetium Lu 177 edotreotide) in neuroendocrine tumours (GEP-NETs)
27 October 2022 – ITM Isotope Technologies today announced that the US FDA has granted the company fast track designation for ITM-11 (Lutetium Lu 177 edotreotide), an investigational radiopharmaceutical for the treatment of gastro-enteropancreatic neuroendocrine tumours.
ITM-11 is being evaluated as a targeted radionuclide therapy in two Phase 3 clinical trials, COMPETE and COMPOSE.
